Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4
3(100.0%)
3Total
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07252804Phase 4Recruiting

Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases

Role: collaborator

NCT07242092Phase 4Not Yet Recruiting

Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs

Role: collaborator

NCT07252791Phase 4Recruiting

Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases

Role: collaborator

NCT01218685Completed

Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants

Role: collaborator

All 4 trials loaded